MDNA:CC News and Press, Medicenna Therapeutics Corp. From 02/13/24

The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA ® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to demonstrate encouraging single-agent activity from the mono...

Synex Renewable Energy Corporation (SXI:CA) is expected to report for Q2 2024 Dye & Durham Limited (DND:CA) is expected to report for Q2 2024 Economic Investment Trust Limited (EVT:CA) is expected to report for quarter end 2023-12-31 Western Forest Products Inc. (WEF:CA) is expect...

Finning International Inc. (FTT:CA) is expected to report $0.94 for Q4 2023 Kure Technologies Inc. (KUR.H:CA) is expected to report for quarter end 2023-11-30 Stingray Group Inc. Subordinate Voting Shares (RAY.A:CA) is expected to report $0.31 for Q3 2024 FirstService Corporation (FSV...

TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the appointment of MNP...

The ABILITY-1 Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA ® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to demonstrate encouraging single-agent activity from the do...

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that its shares will...

Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to patients treated in the external control arm Survival for bizaxofusp-treated patients increased 370% at Year 1 and increased more than 50% at Year 2 TO...

Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic...

Resverlogix Corp. (RVX:CA) is expected to report for Q1 2024 SNC-Lavalin Group Inc. (ATRL:CA) is expected to report $0.37 for Q3 2023 Cascadero Copper Corporation (CCD:CA) is expected to report for quarter end 2023-08-31 Pivotree Inc. (PVT:CA) is expected to report $-0.03 for Q3 2023 ...

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and a...